Forschungsdatenbank

Projektübersicht
Login
Suche

Wieser

Fakultäten » Medizinische Fakultät » Neurologie, Klinik für » Prof. Dr. Heinz-Gregor Wieser (emeritiert) » Wieser

Completed research project

Title / Titel Efficacy and tolerability of new antiepileptic drugs
PDF Abstract (PDF, 14 KB)
Original title / Originaltitel UCB Komet N01175: A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam (1000 to 3000) mg/day oral tablets 250-500 mg b.i.d. compared to sodium valproate (100 to 2000 mg/day oral ER tablets 300-500 mg b.i.d.) and carbamazepine (600 to 1600 mg/day oral CR tablets 200-400 mg b.i.d.) as monotherapy in subjects with newly diagnosed epilepsy
UCB Study NO1237: A multi-center, open-label single arm follow-up evaluating the long-term safety levetiracetam for patients suffering from epilepsy and coming from the Study N=1175


Study A0081005: Pregabalin in partial seizures (PREPS): an open-label, international multicenter add-on therapy trial (Pfizer)
Summary / Zusammenfassung Participation in multi-center studies evaluating efficacy and tolerability of new antiepileptic drugs, such as levetiracetam and pregabalin. Recruitment, treatment period and data management completed. Data analyses is "work in progress"
Publications / Publikationen Steinhoff BJ, Trinka E, Wieser HG; for the DACH-LEV Study Group.
Levetiracetam in patients with refractory epilepsy: Results of the SKATE trial in Austria, Germany and Switzerland. Seizure. 2005;14(7):490-6.

Lachos J, Zumsteg D, Sarnthein J, Wieser HG. Retrospective, open-label study of Levetiracetam in difficult-to-treat epilepsy patients. Medical Science Monitor (submitted)

Keywords / Suchbegriffe Efficacy and tolerability of new antiepileptic drugs, levetiracetam, pregabalin
Project leadership and contacts /
Projektleitung und Kontakte
Prof Heinz Gregor Wieser (Project Leader) hgw@usz.ch
Funding source(s) /
Unterstützt durch
Private Sector (e.g. Industry)
 
In collaboration with /
In Zusammenarbeit mit
UCB Belgium

Pfizer

Switzerland

Duration of Project / Projektdauer Jan 2006 to Nov 2008